LGC has today announced that Marcus Kaeller will join its Board of Directors and Executive Leadership Team (ELT) as Chief Financial Officer (CFO), effective 3rd June 2024. Marcus succeeds Vivid Sehgal, who will leave LGC after almost two and a half years of service. Over the past several months, Vivid has worked closely with the LGC Board and ELT to ensure a smooth transition for Marcus, before leaving the Group at the end of May 2024.
Euan O’Sullivan, President & CEO of LGC, said: “On behalf of our Board and ELT, we are delighted to welcome Marcus to LGC. Marcus brings broad international experience in complex financial leadership roles from the pharmaceutical, medical devices and education industries, as well as substantial experience working with private equity shareholders. As an experienced senior leader, we are confident Marcus will play a key role in driving LGC’s ambitious future growth strategy.”
Euan added: “On behalf of our Board, ELT and colleagues, we would also like to take this opportunity to thank Vivid for the significant contribution he has made to LGC over these past few years, and we wish him every success for the future.”
In response to his appointment, Marcus Kaeller, newly appointed CFO for LGC said: “As a leading global life sciences tools company, LGC’s purpose – Science for a Safer World – certainly resonated with me. I look forward to being part of a customer centric company which plays a key role in enabling transformational science, partnering with our customers to help diagnose, treat, feed and protect the growing global population. I am pleased to be joining LGC at this exciting time and look forward to supporting Euan and the team on our growth journey.”
Marcus was most recently Group CFO and Managing Director of Affidea, the pan-European diagnostic imaging and community-based polyclinic and specialist healthcare services provider – operating 356 centres in 15 European countries. Prior to this, he has held senior financial leadership roles at education multinational Laureate Education, the medical technologies business Stryker, as well as AstraZeneca, having started his career working at Unilever and Accenture.
Marcus has an undergraduate degree in Business Administration and Economics from Edinburgh University, is a Qualified Accountant by the Chartered Institute of Management Accountants in London and has an MBA from London Business School.